General Information of Drug (ID: DMIHQ5G)

Drug Name
IL-2/CD40L-expressing leukemia vaccine Drug Info
Synonyms
Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMIHQ5G

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Not Available [2]
TNF related activation protein (CD40LG) TTIJP3Q CD40L_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TNF related activation protein (CD40LG) DTT CD40LG 3.573 2.406 3.632 3.733
Interleukin-2 (IL2) DTT IL2 0.848 4.548 3.548 4.053
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Chronic lymphocytic leukaemia
ICD Disease Classification 2A82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 7.64E-01 1.04E-02 0.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01604031) Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide. U.S. National Institutes of Health.
2 Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.